TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Clinical Trial of Immediate Versus Standard Antiretroviral Therapy for HIV-infected Adults Presenting With Cryptococcal Meningitis
Brief Summary: The goal of this randomized clinical trial is to compare early versus standard timing of initiation of antiretroviral therapy (ART) with respect to clearance of Cryptococcus neoformans from cerebrospinal fluid (CSF) among HIV-infected adults with Cryptococcal Meningitis.

The investigators hypothesize that early ART mediates more rapid clearance of C. neoformans from CSF, as manifested by a greater rate of decrease in C. neoformans colony forming units (CFUs) during the first 28 days after initiating antifungal treatment.

Secondary hypotheses are that recovery of pathogen specific cellular immunity directed at C. neoformans, as manifested by increases in the number and function of C. neoformans-specific peripheral blood mononuclear cells is associated with 1) ART and 2) pathogen clearance. In addition, patients randomized to the intervention arm will have more rapid clearance of antigen levels in CSF and serum and will have a lower incidence of grade 3 and 4 Adverse events.


Options:
A: Arm Label: Early antiretroviral therapy; Type: EXPERIMENTAL; Interventions: Other: Early antiretroviral therapy | Arm Label: Standard antiretroviral therapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Early antiretroviral therapy; Assigned to Arm(s): Early antiretroviral therapy
B: Intervention Type: DRUG; Name: Emtricitabine/tenofovir disoproxil fumarate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lopinavir/ritonavir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Stavudine; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole, Drug: Fixed dose - Stavudine, lamivudine and Nevirapine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole, Drug: Fixed dose - Stavudine, Lamivudine, Nevirapine | Intervention Type: DRUG; Name: Fluconazole; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Fixed dose - Stavudine, lamivudine and Nevirapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fixed dose - Stavudine, Lamivudine, Nevirapine; Assigned to Arm(s): 2
D: Arm Label: MJAP Clinics Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: START | Arm Label: MJAP Clinics Pre-Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: START; Assigned to Arm(s): MJAP Clinics Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study
Brief Summary: Intravenous cyclophosphamide is considered to be the standard of care for treatment of proliferative lupus nephritis. However, its use is limited by potentially severe toxic effects. Cyclosporine A has been suggested to be an efficient and safe treatment alternative to cyclophosphamide. In a randomized, multicenter, open-label, controlled trial the investigators sought to compare the efficacy of oral cyclosporine A with intravenous pulse cyclophosphamide to induce durable remission in patients with lupus nephritis III-IV.


Options:
A: Arm Label: Abatacept 30 mg/kg+Corticosteroids+MMF; Type: EXPERIMENTAL; Interventions: Drug: Corticosteroids (prednisone or prednisolone), Drug: Abatacept, Drug: Mycophenolate mofetil (MMF) | Arm Label: Abatacept 10 mg/kg+Corticosteroids+MMF; Type: EXPERIMENTAL; Interventions: Drug: Corticosteroids (prednisone or prednisolone), Drug: Abatacept, Drug: Mycophenolate mofetil (MMF) | Arm Label: Placebo+Corticosteroids+MMF; Type: EXPERIMENTAL; Interventions: Drug: Corticosteroids (prednisone or prednisolone), Drug: Mycophenolate mofetil (MMF) | Arm Label: Abatacept 10mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Abatacept | Intervention Type: DRUG; Name: Corticosteroids (prednisone or prednisolone); Assigned to Arm(s): Abatacept 10 mg/kg+Corticosteroids+MMF, Abatacept 30 mg/kg+Corticosteroids+MMF, Placebo+Corticosteroids+MMF | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept 30 mg/kg+Corticosteroids+MMF | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept 10 mg/kg+Corticosteroids+MMF | Intervention Type: DRUG; Name: Mycophenolate mofetil (MMF); Assigned to Arm(s): Abatacept 10 mg/kg+Corticosteroids+MMF, Abatacept 30 mg/kg+Corticosteroids+MMF, Placebo+Corticosteroids+MMF | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept 10mg/kg
B: Intervention Type: DRUG; Name: Abetimus sodium (LJP 394); Assigned to Arm(s): N/A
C: Arm Label: FK506+MMF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Multitherapy | Intervention Type: DRUG; Name: Multitherapy; Assigned to Arm(s): FK506+MMF
D: Arm Label: Cyclosporine A; Type: EXPERIMENTAL; Interventions: Drug: Cyclosporine A | Arm Label: Cyclophosphamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide | Intervention Type: DRUG; Name: Cyclosporine A; Assigned to Arm(s): Cyclosporine A | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cyclophosphamide

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Exploratory Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess The Pharmacodynamics Of CP-690,550, Administered Orally Twice Daily (BID) For 4 Weeks, In Subjects With Active Rheumatoid Arthritis
Brief Summary: To explore the effect of CP-690,550 on blood and synovial markers in subjects with rheumatoid arthritis. To evaluate the safety, tolerability and efficacy of CP-690,550.


Options:
A: Arm Label: Certolizumab pegol 400 mg and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Certolizumab pegol 200 mg and placebo; Type: EXPERIMENTAL; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 400 mg and placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo, Certolizumab pegol 400 mg and placebo, Placebo
B: Arm Label: Placebo followed by Certolizumab Pegol (CZP); Type: OTHER; Interventions: Other: Placebo, Biological: Certolizumab Pegol (CZP) 200 mg, Biological: Certolizumab Pegol (CZP) 400 mg | Arm Label: Certolizumab Pegol (CZP); Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol (CZP) 200 mg, Biological: Certolizumab Pegol (CZP) 400 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo followed by Certolizumab Pegol (CZP) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol (CZP) 200 mg; Assigned to Arm(s): Certolizumab Pegol (CZP), Placebo followed by Certolizumab Pegol (CZP) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol (CZP) 400 mg; Assigned to Arm(s): Certolizumab Pegol (CZP), Placebo followed by Certolizumab Pegol (CZP)
C: Arm Label: CP-690,550 + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 + methotrexate | Arm Label: Placebo + methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + Methotrexate | Intervention Type: DRUG; Name: CP-690,550 + methotrexate; Assigned to Arm(s): CP-690,550 + methotrexate | Intervention Type: DRUG; Name: Placebo + Methotrexate; Assigned to Arm(s): Placebo + methotrexate
D: Arm Label: methotrexate + adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Adalimumab | Arm Label: methotrexate + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): methotrexate + adalimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): methotrexate + placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Exploratory Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess The Pharmacodynamics Of CP-690,550, Administered Orally Twice Daily (BID) For 4 Weeks, In Subjects With Active Rheumatoid Arthritis
Brief Summary: To explore the effect of CP-690,550 on blood and synovial markers in subjects with rheumatoid arthritis. To evaluate the safety, tolerability and efficacy of CP-690,550.


Options:
A: Arm Label: Tocilizumab 4 mg/kg + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: Tocilizumab 8 mg/kg + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: Placebo + Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): Tocilizumab 4 mg/kg + Methotrexate, Tocilizumab 8 mg/kg + Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Placebo + Methotrexate, Tocilizumab 4 mg/kg + Methotrexate, Tocilizumab 8 mg/kg + Methotrexate
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Drug: MTX | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Infliximab, Drug: MTX | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Infliximab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): 2
C: Arm Label: CP-690,550 + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 + methotrexate | Arm Label: Placebo + methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + Methotrexate | Intervention Type: DRUG; Name: CP-690,550 + methotrexate; Assigned to Arm(s): CP-690,550 + methotrexate | Intervention Type: DRUG; Name: Placebo + Methotrexate; Assigned to Arm(s): Placebo + methotrexate
D: Arm Label: 5mg; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 | Arm Label: 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Sequence 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Placebo Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biologic TNFi | Intervention Type: DRUG; Name: CP 690,550; Assigned to Arm(s): 5mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 10 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Sequence 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Sequence 2 | Intervention Type: BIOLOGICAL; Name: Biologic TNFi; Assigned to Arm(s): adalimumab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Exploratory Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess The Pharmacodynamics Of CP-690,550, Administered Orally Twice Daily (BID) For 4 Weeks, In Subjects With Active Rheumatoid Arthritis
Brief Summary: To explore the effect of CP-690,550 on blood and synovial markers in subjects with rheumatoid arthritis. To evaluate the safety, tolerability and efficacy of CP-690,550.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: etanercept | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1
B: N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3
D: Arm Label: CP-690,550 + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 + methotrexate | Arm Label: Placebo + methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + Methotrexate | Intervention Type: DRUG; Name: CP-690,550 + methotrexate; Assigned to Arm(s): CP-690,550 + methotrexate | Intervention Type: DRUG; Name: Placebo + Methotrexate; Assigned to Arm(s): Placebo + methotrexate

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mastering Hospital Antibiotic Resistance, a Cluster Randomized Intervention Study in Intensive Care Units Throughout Europe (Work Package 3)
Brief Summary: Colonization of patients with Antimicrobial Resistant Bacteria (AMRB) like Methicillin Resistant Staphylococcus Aureus (MRSA), Vancomycin-Resistant Enterococcus (VRE) and Extended-Spectrum Beta-Lactamases (ESBL) enterobacteriaceae leads to infections; and ultimately to adverse outcomes (eg prolonged hospital stay, death). This is an urgent problem in Europe, especially in Intensive Care Units (ICUs).

In this trial, colonization of patients with these AMRB will be assessed in the baseline period (6m). In phase 2 the effect of a Hygiene Improvement Program, including Chlorhexidine body washings and a Hand Hygiene training program, will be assessed (6m). In phase 3 units will be randomized to either Active Surveillance with Chromagar based tests or a Molecular based tests.

Study Hypothesis: the abovementioned interventions will reduce ICU-acquired colonization rates with MRSA, VRE and ESBL.


Options:
A: Arm Label: Chromogenic Arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Chromogenic surveillance | Arm Label: Molecular Arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Molecular surveillance | Intervention Type: OTHER; Name: Chromogenic surveillance; Assigned to Arm(s): Chromogenic Arm | Intervention Type: OTHER; Name: Molecular surveillance; Assigned to Arm(s): Molecular Arm
B: Arm Label: Active Screening; Type: OTHER; Interventions: Device: nucleic acid amplification of nasal swab; nasal swab culture | Arm Label: Passive Screening; Type: OTHER; Interventions: Other: Nasal swab culture | Intervention Type: DEVICE; Name: nucleic acid amplification of nasal swab; nasal swab culture; Assigned to Arm(s): Active Screening | Intervention Type: OTHER; Name: Nasal swab culture; Assigned to Arm(s): Passive Screening
C: Intervention Type: PROCEDURE; Name: Intensive Control Strategy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Standard Control Strategy; Assigned to Arm(s): N/A
D: Arm Label: Beta-blocker adherence after an AMI; Type: EXPERIMENTAL; Interventions: Behavioral: Beta-blocker adherence after an AMI | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Beta-blocker adherence after an AMI; Assigned to Arm(s): Beta-blocker adherence after an AMI

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mastering Hospital Antibiotic Resistance, a Cluster Randomized Intervention Study in Intensive Care Units Throughout Europe (Work Package 3)
Brief Summary: Colonization of patients with Antimicrobial Resistant Bacteria (AMRB) like Methicillin Resistant Staphylococcus Aureus (MRSA), Vancomycin-Resistant Enterococcus (VRE) and Extended-Spectrum Beta-Lactamases (ESBL) enterobacteriaceae leads to infections; and ultimately to adverse outcomes (eg prolonged hospital stay, death). This is an urgent problem in Europe, especially in Intensive Care Units (ICUs).

In this trial, colonization of patients with these AMRB will be assessed in the baseline period (6m). In phase 2 the effect of a Hygiene Improvement Program, including Chlorhexidine body washings and a Hand Hygiene training program, will be assessed (6m). In phase 3 units will be randomized to either Active Surveillance with Chromagar based tests or a Molecular based tests.

Study Hypothesis: the abovementioned interventions will reduce ICU-acquired colonization rates with MRSA, VRE and ESBL.


Options:
A: Arm Label: Arm 1: Usual Care-Active Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm 2: Targeted Decolonization; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine bath and nasal mupirocin | Arm Label: Arm 3: Universal Decolonization; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine bath and nasal mupirocin | Intervention Type: DRUG; Name: Chlorhexidine bath and nasal mupirocin; Assigned to Arm(s): Arm 2: Targeted Decolonization, Arm 3: Universal Decolonization
B: Arm Label: chlorhexidine gluconate (CHG); Type: EXPERIMENTAL; Interventions: Drug: 2% chlorhexidine gluconate impregnated cloth | Arm Label: Soap & Water; Type: ACTIVE_COMPARATOR; Interventions: Other: Daily bathing with Bar soap | Intervention Type: DRUG; Name: 2% chlorhexidine gluconate impregnated cloth; Assigned to Arm(s): chlorhexidine gluconate (CHG) | Intervention Type: OTHER; Name: Daily bathing with Bar soap; Assigned to Arm(s): Soap & Water
C: Arm Label: Chromogenic Arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Chromogenic surveillance | Arm Label: Molecular Arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Molecular surveillance | Intervention Type: OTHER; Name: Chromogenic surveillance; Assigned to Arm(s): Chromogenic Arm | Intervention Type: OTHER; Name: Molecular surveillance; Assigned to Arm(s): Molecular Arm
D: Arm Label: Soap bathing; Type: PLACEBO_COMPARATOR; Interventions: Drug: Soap | Arm Label: 2% chlorhexidine wipes; Type: EXPERIMENTAL; Interventions: Drug: 2% chlorhexidine wipe | Intervention Type: DRUG; Name: 2% chlorhexidine wipe; Assigned to Arm(s): 2% chlorhexidine wipes | Intervention Type: DRUG; Name: Soap; Assigned to Arm(s): Soap bathing

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Weighted Bag Versus Inner Thigh Taping for Cervical Ripening With a Foley Catheter Prior to an Induction of Labor
Brief Summary: This study aims to determine what type of traction, weighted bag or inner thigh taping, on foley catheters for cervical ripening results in a greater cervical dilation and shorter length of labor.

The primary outcomes are post-ripening dilation of 3 cm or more and time to delivery.

The secondary outcomes are patient pain/comfort rating and method of delivery. The investigators hypothesize that the use a weighted bag will result in a 20% increase in post-ripening dilation of at least 3 cm and a shorter average length of labor.


Options:
A: Arm Label: weighted bag; Type: ACTIVE_COMPARATOR; Interventions: Other: weighted bag | Arm Label: leg taping; Type: ACTIVE_COMPARATOR; Interventions: Other: leg taping | Intervention Type: OTHER; Name: weighted bag; Assigned to Arm(s): weighted bag | Intervention Type: OTHER; Name: leg taping; Assigned to Arm(s): leg taping
B: Arm Label: Expectant management (EM) arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Induction of Labor (IOL) arm; Type: EXPERIMENTAL; Interventions: Procedure: Induction of Labor | Intervention Type: PROCEDURE; Name: Induction of Labor; Assigned to Arm(s): Induction of Labor (IOL) arm
C: Arm Label: FOLEY BALLOON; Type: ACTIVE_COMPARATOR; Interventions: Device: FOLEY BALLOON | Arm Label: CERVIDIL; Type: ACTIVE_COMPARATOR; Interventions: Drug: CERVIDIL (Dinoprostone) | Intervention Type: DRUG; Name: CERVIDIL (Dinoprostone); Assigned to Arm(s): CERVIDIL | Intervention Type: DEVICE; Name: FOLEY BALLOON; Assigned to Arm(s): FOLEY BALLOON
D: Intervention Type: DEVICE; Name: Transcervical Foley Catheter; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Transcervical Foley Catheter with an EASI; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Weighted Bag Versus Inner Thigh Taping for Cervical Ripening With a Foley Catheter Prior to an Induction of Labor
Brief Summary: This study aims to determine what type of traction, weighted bag or inner thigh taping, on foley catheters for cervical ripening results in a greater cervical dilation and shorter length of labor.

The primary outcomes are post-ripening dilation of 3 cm or more and time to delivery.

The secondary outcomes are patient pain/comfort rating and method of delivery. The investigators hypothesize that the use a weighted bag will result in a 20% increase in post-ripening dilation of at least 3 cm and a shorter average length of labor.


Options:
A: Arm Label: Cervical foley & Misoprostol; Type: EXPERIMENTAL; Interventions: Device: Cervical Foley & Misoprostol | Arm Label: Misoprostol only; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol Alone | Arm Label: Cervical foley alone; Type: EXPERIMENTAL; Interventions: Device: Cervical Foley Alone | Arm Label: Cervical foley & Pitocin; Type: EXPERIMENTAL; Interventions: Device: Cervical Foley & Pitocin | Intervention Type: DEVICE; Name: Cervical Foley & Misoprostol; Assigned to Arm(s): Cervical foley & Misoprostol | Intervention Type: DRUG; Name: Misoprostol Alone; Assigned to Arm(s): Misoprostol only | Intervention Type: DEVICE; Name: Cervical Foley Alone; Assigned to Arm(s): Cervical foley alone | Intervention Type: DEVICE; Name: Cervical Foley & Pitocin; Assigned to Arm(s): Cervical foley & Pitocin
B: Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Foley Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Foley Catheter | Intervention Type: DEVICE; Name: Foley Catheter; Assigned to Arm(s): Foley Catheter | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol
C: Arm Label: weighted bag; Type: ACTIVE_COMPARATOR; Interventions: Other: weighted bag | Arm Label: leg taping; Type: ACTIVE_COMPARATOR; Interventions: Other: leg taping | Intervention Type: OTHER; Name: weighted bag; Assigned to Arm(s): weighted bag | Intervention Type: OTHER; Name: leg taping; Assigned to Arm(s): leg taping
D: Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: Foley Catheter and Oxytocin; Type: EXPERIMENTAL; Interventions: Device: Foley Catheter, Drug: Oxytocin | Intervention Type: DEVICE; Name: Foley Catheter; Assigned to Arm(s): Foley Catheter and Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Foley Catheter and Oxytocin, Oxytocin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Tolerability of the Combination of LIthium and CArbamazepine Compared to Lithium and VALproic Acid in the Treatment of Young Bipolar Patients
Brief Summary: The purpose of this study is to determine the efficacy of the combination of lithium and carbamazepine compared with lithium and valproate treating young bipolar patients.


Options:
A: Arm Label: Lithium (LI); Type: EXPERIMENTAL; Interventions: Drug: Lithium (LI) | Arm Label: Divalproex (DV); Type: EXPERIMENTAL; Interventions: Drug: Divalproex (DV) | Intervention Type: DRUG; Name: Lithium (LI); Assigned to Arm(s): Lithium (LI) | Intervention Type: DRUG; Name: Divalproex (DV); Assigned to Arm(s): Divalproex (DV)
B: Intervention Type: DRUG; Name: Divalproex Sodium Extended-Release Tablets; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Divalproex | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Divalproex; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: lithium plus carbamazepine; Type: EXPERIMENTAL; Interventions: Drug: lithium plus carbamazepine | Arm Label: lithium plus valproate; Type: ACTIVE_COMPARATOR; Interventions: Drug: lithium plus valproate | Intervention Type: DRUG; Name: lithium plus carbamazepine; Assigned to Arm(s): lithium plus carbamazepine | Intervention Type: DRUG; Name: lithium plus valproate; Assigned to Arm(s): lithium plus valproate

Answer: D